Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00073840 · ClinicalTrials.gov registry record · Phase 3

Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older With Asthma

A Phase 3 study of Asthma, sponsored by Sumitomo Pharma America.

Completed
Registry status
Phase 3
Development phase
386
Enrollment target
20
Study locations

NCT00073840 is a Phase 3 study of Asthma that has completed, run by Sumitomo Pharma America. The registered enrollment target is 386 participants, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (75% lower). The trial reports 20 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00073840, a Phase 3 study of Asthma, has completed, sponsored by Sumitomo Pharma America.

COMPLETED
Registry status
Phase 3
Development phase
386 participants
Enrollment target
20
Study locations

Study Summary

The primary objective of this study is to investigate the efficacy of levalbuterol 90 ug (2 actuations, 45 ug each) versus placebo (2 actuations) in the treatment and prevention of bronchoconstriction in adolescent and adult subjects with asthma, with all treatments administered 4 times a day (QID).

Conditions Studied

Interventions

  • DRUG levalbuterol

Study Locations (20)

California

  • Integrated Research Group - Corona
  • Radiant Research, Inc. - Encinitas
  • Allergy & Asthma Specialists Medical Group - Huntington Beach
  • Asthma, Allergy & Respiratory Care Center - Long Beach
  • Allergy Research Foundation, Inc. - Los Angeles
  • Madera Family Medical Group - Madera
  • Southern California Research - Mission Viejo
  • Comprehensive Allergy Services - Oakland
  • Clinical Trials of Orange County - Orange
  • Allergy Associates Medical Group - San Diego
  • Allergy & Asthma Medical Group & Research Center - San Diego
  • Allergy & Asthma Assoc. of Santa Clara Valley Research Center - San Jose
  • West Coast Clinical Trials - Signal Hill
  • Allergy & Asthma Medical Group of Diablo Valley, Inc. - Walnut Creek

Georgia

  • Watts Medical Research - Barnesville
  • The Allergy & Asthma Clinical Research Center - Conyers
  • Aeroallergy Research Laboratories of Savannah, Inc. - Savannah

Alabama

  • Allergy & Asthma Center, LLC - Oxford

Arizona

  • Alta Clinical Research - Tucson

Colorado

  • 1st Allergy & Asthma Clinical Research Ctr - Thornton

Trial Details

FieldValue
Enrollment Target 386 participants
Start Date 2002-12
Est. Completion 2003-06
Phase Phase 3

Sponsor

Sumitomo Pharma America

168 total trials

What the Registry Record Tells You About NCT00073840

The ClinicalTrials.gov registry entry for NCT00073840 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 386 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (75% lower). The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 1 intervention - of which levalbuterol is the first listed.

NCT00073840 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Georgia, Alabama.

Frequently Asked Questions

What is clinical trial NCT00073840 about?

NCT00073840 is a clinical study titled "Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older With Asthma". The primary objective of this study is to investigate the efficacy of levalbuterol 90 ug (2 actuations, 45 ug each) versus placebo (2 actuations) in the treatment and prevention of bronchoconstriction in adolescent and adult subjects with asthma, with all treatments administered 4 times a day (QID).

What is the current status of trial NCT00073840?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 386 participants. The study started on 2002-12. Estimated completion is 2003-06.

What conditions does trial NCT00073840 study?

This clinical trial studies the following conditions: Asthma.

What interventions are being tested in trial NCT00073840?

The interventions under investigation include: levalbuterol (DRUG).

Who is sponsoring clinical trial NCT00073840?

This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00073840 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Asthma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.